Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: Why we need a consensus

Pediatric Drugs

Volumn 14, Issue 1, 2012, Pages 7-12

  Broughton, Thomas ^a   Armon, Kate ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

arthritis; DMARD; idiopathic; juvenile; remission; withdrawal

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TRIAMCINOLONE;

ARTHRITIS; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REMISSION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CONSENSUS; DRUG ADMINISTRATION SCHEDULE; HUMANS; REMISSION INDUCTION; TIME FACTORS;

EID: 83455165000     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11595980-000000000-00000     Document Type: Article

References (38)

1. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002; 29 (7): 1520-30
2. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2
3. Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29: 1989-99
4. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359 (8): 810-20
5. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326 (16): 1043-9
6. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome. Rheumatology (Oxford) 2002; 41 (12): 1428-35
7. Wallace CA, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31 (11): 2290-4
8. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52 (11): 3554-62
9. Wallace CA, Ravelli A, Huang B, et al. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006; 33 (4): 789-95
10. Flatø B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: A case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003; 30 (2): 386-93
11. Marti P, Molinari L, Bolt IB, et al. Factors influencing the efficacy of intraarticular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr 2008; 167 (4): 425-30
12. Albers HM,Brinkman DM, Kamphuis SS, et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010; 62 (2): 204-12
13. Vilca I, Munitis PG, Pistorio A, et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: Analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010; 69 (8): 1479-83
14. Hull RG. Management guidelines for arthritis in children. Rheumatology (Oxford) 2001; 40 (11): 1308
15. Davies K, Cleary G, Foster H, et al. BSPAR standards of care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49 (7): 1406-8
16. Woo P. Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol 2009; 21 (5): 552-7
17. Prince FH, Otten MH, van Suijlekom-Smit LW. Diagnosis and management of juvenile idiopathic arthritis. BMJ 2010; 341: C6434
18. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63: 465-82
19. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50 (7): 2191-201
20. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43 (8): 1849-57
21. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369 (9563): 767-78
22. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38 (2): 211-20
23. Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol Suppl 1992; 33: 6-10
24. Lovell D. Update on treatment of arthritis in children: New treatments, new goals. Bull NYU Hosp Jt Dis 2006; 64 (1-2): 72-6
25. NICE. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Technology appraisal no. 35. London: NICE, 2002
26. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58 (5): 1496-504
27. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011; 50 (1): 189-95
28. FDA. Tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009 [online]. Available from URL: Http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm175843.htm [Accessed 2011 Oct]
29. Deighton C, Scott DL. Treating inflammatory arthritis early. BMJ 2010; 341: C7384
30. Foell D, Frosch M, Schulze zur Wiesch A, et al. Methotrexate treatment in juvenile idiopathic arthritis: When is the right time to stop? Ann Rheum Dis 2004; 63 (2): 206-8
31. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: A randomized clinical trial. JAMA 2010; 303 (13): 1266-73
32. Oen K, Malleson PN, Cabral DA, et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2005; 44 (9): 1115-21
33. Broughton T, Armon K. Juvenile idiopathic arthritis: How do clinicians define remission and withdraw etanercept? Arch Dis Child 2010; 95 Suppl. 1: A23-38
34. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 2011; 50 (1): 214-21
35. Lurati A, Salmaso A, Gerloni V, et al. Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: A cohort study of 761 consecutive cases. J Rheumatol 2009; 36 (7): 1532-5
36. Schulze zur Wiesch A, Foell D, Frosch M, et al. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22 (3): 368-73
37. Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60 (3): 883-91
38. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628-37